# Silvia Sabatino

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/silvia-sabatino/

## Facts

| Field | Value |
| --- | --- |
| Citations | 302 |
| Field | Immune cells in cancer |
| h-index | 5 |
| i10-index | 2 |
| Last Known Institution | Eli Lilly (United States) |
| OpenAlex ID | https://openalex.org/A5080020655 |
| Works | 36 |

## Researcher papers

- [GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy](https://scholariq.org/papers/glut1-expression-in-tumor-associated-neutrophils-promotes-lung-cancer-growth-and/)
- [Combined deletion of Glut1 and Glut3 impairs lung adenocarcinoma growth](https://scholariq.org/papers/combined-deletion-of-glut1-and-glut3-impairs-lung-adenocarcinoma-growth/)
- [Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)](https://scholariq.org/papers/ixekizumab-is-effective-in-the-long-term-management-in-moderate-to-severe-plaque/)
- [Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch](https://scholariq.org/papers/baricitinib-improvement-across-regions-in-atopic-dermatitis-patients-with/)
- [Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO)](https://scholariq.org/papers/effectiveness-of-biologics-patient-reported-outcomes-and-clinical-photography-in/)
- [Analysis of Drug Utilization in Patients with Psoriasis: A Real-World Retrospective Study Among the Italian Population](https://scholariq.org/papers/analysis-of-drug-utilization-in-patients-with-psoriasis-a-real-world/)
- [Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023](https://scholariq.org/papers/real-world-evidence-for-baricitinib-in-the-treatment-of-atopic-dermatitis-and/)
- [Comparative Effectiveness and Durability of Biologics Through 24 Months for Patients with Moderate-to-Severe Psoriasis: Results from the International, Observational Psoriasis Study of Health Outcomes (PSoHO)](https://scholariq.org/papers/comparative-effectiveness-and-durability-of-biologics-through-24-months-for/)
- [Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective](https://scholariq.org/papers/cost-effectiveness-analysis-of-baricitinib-versus-dupilumab-for-moderate-to/)
- [Baricitinib Provides Significant Improvements in Quality of Life and Functioning in Adults with Moderate-to-Severe Atopic Dermatitis with Baseline Body Surface Area ≤ 40% and Severe Itch](https://scholariq.org/papers/baricitinib-provides-significant-improvements-in-quality-of-life-and-functioning/)
- [Burden, Treatment Patterns and Real-World Barriers to Prescribing Advanced Treatments in Adults with Atopic Dermatitis in Brazil and Colombia](https://scholariq.org/papers/burden-treatment-patterns-and-real-world-barriers-to-prescribing-advanced/)

## Researcher topics

- [Immune cells in cancer](https://scholariq.org/topics/immune-cells-in-cancer/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Cancer, Hypoxia, and Metabolism](https://scholariq.org/topics/cancer-hypoxia-and-metabolism/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Mechanisms of cancer metastasis](https://scholariq.org/topics/mechanisms-of-cancer-metastasis/)

## Researcher university

- [Eli Lilly (United States)](https://scholariq.org/institutions/eli-lilly-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.